Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicuRx Pharmaceuticals has received a US patent from the USPTO covering the composition of its clinical candidate, MRX-I.
Subscribe to our email newsletter
The antibacterial oxazolidinone targets infections due to multi-drug resistant Gram-positive pathogens.
MicuRx president and chief executive officer Zhengyu Yuan said, "With a scarcity of new antibiotics in development and ever-increasing bacterial resistance, we believe that MRX-I, with its high antimicrobial potency and enhanced safety profile, could offer a valuable option for treatment of infections caused by multi-drug resistant Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE)."
MicuRx’s agents directly address the problem of multi-drug resistant bacteria, with a potential for deployment in both hospital and community-based settings, the company said.